Login / Signup
Christopher Frantz
ORCID
Publication Activity (10 Years)
Years Active: 2023-2024
Publications (10 Years): 2
Top Topics
Escherichia Coli
Hodgkin Lymphoma
Magnetic Resonance
Cell Adhesion
Top Venues
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Haley D Neff-LaFord
,
Sarah A Carratt
,
Christopher Carosino
,
Nancy Everds
,
Kristen A Cardinal
,
Steven Duniho
,
Melissa M Schutten
,
Christopher Frantz
,
Christina Zuch de Zafra
,
Eric B Harstad
The vedotin antibody-drug conjugate payload drives platform-based nonclinical safety and pharmacokinetic profiles.
Molecular cancer therapeutics
(2024)
Robert P Lyon
,
Mechthild Jonas
,
Christopher Frantz
,
Esther S Trueblood
,
Roma Yumul
,
Lori Westendorf
,
Christopher J Hale
,
Jackie L Stilwell
,
Narayana Yeddula
,
Katie M Snead
,
Vineet Kumar
,
Gabriela I Patilea-Vrana
,
Kerry Klussman
,
Maureen C Ryan
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
Molecular cancer therapeutics
(2023)